The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Are GLP-1 agonists the answer to our obesity epidemic?
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, HCPs know that they will be responsible for the prescription and ongoing monitoring of these medications and are cautious about managing this new wave of pharmacotherapy within their current capacity 53 and taking on additional responsibilities for a chronic relapsing condition.”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Effective strategies in ending weight stigma in healthcare
Talumaa, B., Brown, A., Batterham, R. L., & Kalea, A. Z. (2022) · Obesity Reviews · doi:10.1111/obr.13494 · Cited by 250
Chakravorty, T. A. (2021) · BMJ · doi:10.1136/bmj.n2830 · Cited by 17
Is There Sustained Weight Loss after Discontinuation of GLP-1 Agonist for Obesity Treatment?
Caro, R., Samsel, D., & Savel, P. (2023) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001786 · Cited by 7
Cited by
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
How to 'drug' our way out of the obesity crisis (or not): the roll-out of semaglutide.
Khan, N. (2024) · The British journal of general practice : the journal of the Royal College of General Practitioners · doi:10.3399/bjgp24x737241 · Cited by 2
GPs’ perspectives on GLP-1RAs for obesity management: a qualitative study in England
Keating, S., Wild, C. E. K., Scragg, J. H., Dixon, S., Treadwell, J. S., Hinton, L., & Jebb, S. A. (2025) · British Journal of General Practice · doi:10.3399/bjgp.2025.0065 · Cited by 3
Metadata
- Authors
- Dapre, E.
- Corresponding author
- Dapre, Elizabeth
- ORCID
- Dapre, Elizabeth
- Venue
- British Journal of General Practice
- Published
- 2023-07-27
- Volume
- 73
- Issue
- 733
- Pages
- 365-365
- ISSN
- 0960-1643 (ISSN-L)
- 1478-5242
- PMC
- PMC10405951
- OpenAlex
- W4385326107
- Cited by
- 3
- References
- 4
- Citations by year
- 2025: 2 · 2024: 1
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of General Practice (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- GLP-1 receptor agonists, obesity, obesity treatment, weight loss
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Are GLP-1 agonists the answer to our obesity epidemic? https://app.cochat.ai/papers/10.3399/bjgp23x734589
- The paper
- Dapre, E. (2023). Are GLP-1 agonists the answer to our obesity epidemic? British Journal of General Practice. https://doi.org/10.3399/bjgp23x734589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
